Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-infectives - BlueWillow Biologics

Drug Profile

Research programme: anti-infectives - BlueWillow Biologics

Alternative Names: NB-005; NB-201; NB-401; NB-402; Topical nanoemulsions for bacterial infections - BlueWillow Biologics; Vaginitis nanoemulsion (NB Prototype-1); Vaginitis nanoemulsion (NB Prototype-2)

Latest Information Update: 09 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoBio Corporation
  • Developer BlueWillow Biologics; NanoBio Corporation; University of Michigan Medical School
  • Class
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Burn infections; Cystic fibrosis-associated respiratory tract infections; Herpes simplex virus infections; Influenza virus infections; Methicillin-resistant Staphylococcus aureus infections; Vaginitis; Wound infections
  • Discontinued Herpes zoster

Most Recent Events

  • 07 May 2018 NanoBio Corporation is now called BlueWillow Biologics
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Burn-infections in USA (Topical, Lotion)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cystic-fibrosis-associated-respiratory-tract-infections in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top